All In Biotech

Drug Trial Radar · NCT06521034

First-in-Human Phase I/II Study of FHND-9041 in Patients With EGFR Mutated Advanced Non-Small Cell Lung Cancer

Omprehensive First-in-Human Phase I/II Study of FHND-9041 in Patients With EGFR Mutated Advanced Non-Small Cell Lung Cancer

Last checked: Nov 19, 2026Latest source record: Jul 25, 2024 (this record)Source: ClinicalTrials.govMethods & limitations

Completed

Status

Completed

Enrollment

124

Actual

Start

Jun 27, 2019

Primary completion

May 17, 2021

Study completion May 17, 2021

Sponsor

Lead sponsor
Yongchang ZhangAcademic, hospital or other
Sponsor type
Academic, hospital or other
Collaborators
Jiangsu Chia Tai Fenghai Pharmaceutical Co., Ltd.
First posted
Jul 25, 2024

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 1 / Phase 2
Allocation
Non randomized
Model
Single group
Masking
None
Primary purpose
Treatment
FDA-regulated drug
No
Who can join
All sexes, from 18 years, up to 75 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

FHND-9041 capsule is a novel third-generation EGFR inhibitor targeting EGFR-sensitive mutations. This first-in-human study is a single-arm, multi-center, open-label, non-randomized Phase Ⅰ/II trial. It aims to evaluate the tolerability, safety, pharmacokinetics, and anti-tumor activity of FHND-9041 in patients with NSCLC harboring the EGFRT790M mutation, particularly those acquiring resistance to prior EGFR-TKI treatment. Additionally, the study seeks to determine the Recommended Phase II Dose (RP2D) of FHND-9041and assess its efficacy as a first-line treatment for patients with locally advanced or metastatic NSCLC harboring EGFR-sensitive mutations.

Conditions

  • Non-small Cell Lung Cancer
  • EGFR Gene Mutation
  • EGFR-TKI Sensitizing Mutation

Interventions

  • FHND-9041Drug

    In Phase I, using a "3+3" design, dose escalation and expansion studies were conducted at doses of 40, 80, 120 and 180 mg/day. At least 3 patients were enrolled in each dose arm, and no dose-limiting toxicities were observed. With a plateau observed at 120 mg/day, the 80 mg/d and 120mg/d groups were selected for dose expansion. The 80mg/d queue has expanded by 36 patients, and the 120mg/d queue has expanded by 39 patients. In Phase Ⅱ, after comprehensive analysis and consultation, at least 30 patients were enrolled according to the inclusion and exclusion criteria. 37 patients with locally advanced or metastatic EGFR-mutated NSCLC receiving first-line treatment were enrolled.

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Pharmacokinetic Parameters of Maximum Serum Concentration (Cmax) after cycle 1Time frame: through study completion, an average of 1 year
  2. Pharmacokinetic Parameters Area Under the Concentration-Time Curve After Cycle 1Time frame: through study completion, an average of 1 year

Locations

1 site in 1 country. Site status is shown where the registry gives one.

  • Yongchang Zhang

    Changsha, Hunan, China

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.